Changes in Hong Kong stocks | Zhaoyan Pharmaceutical (06127) has risen more than 10%, and the price of experimental monkeys has recently skyrocketed, institutions say the gap between supply and demand may continue to expand

The Zhitong Finance App learned that Zhaoyan New Pharmaceutical (06127) rose by more than 10%. As of press release, it had risen 9.61% to HK$17.8, with a turnover of HK$172 million.

According to the news, according to a report from Red Star Capital, the unit price of crab-eating monkeys quietly surpassed the 100,000 yuan mark in early December. Over the past few days, as a monkey buyer, Red Star Capital has learned from many experimental monkey breeding companies in Guangdong, Guangxi, Yunnan, etc., that there is a shortage of supply of crab-eating monkeys, and their value has risen to 120,000 to 130,000 yuan. Some monkey farms said that the monkeys for the first half of next year have already been ordered.

According to estimates by Fangzheng Securities, the supply of experimental monkeys is expected to be about 48,000 to 52,400 monkeys per year from 2025 to 2027, and the demand for experimental monkeys is about 513-62,600 monkeys per year. In the short term, due to the recovery in new drug development, the consumption of experimental monkeys will increase, and the supply side is more difficult to improve in the short term, and the gap between supply and demand may continue to expand. China Merchants Securities pointed out in a research report released in July this year that Zhaoyan Pharmaceutical's acquisition of Monkey Farm to integrate the industrial chain is expected to benefit from subsequent price increases and profits.